U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07319676) titled 'Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas' on Dec. 21, 2025.
Brief Summary: This is a single center, open label, phase 1 lead in to determine Recommended Phase 2 Dose (RP2D), followed by a phase 2 trial to evaluate the safety and efficacy of Epo-R-CD19 CAR T with or without CD22 CAR T-cells infused into patients with B cell lymphoma.
The study will have the following parts:
* Screening
* Pre-infusion (cell product preparation and bridging) and infusion (lymphodepletion)
* Primary efficacy endpoints
* Long term follow up
Patients who have high risk B cell lymphoma or relapsed/refractory B cell lymp...